CD274 and non-small cell lung carcinoma: Overall, four phase III randomized studies demonstrated that PD1/PD-L1 inhibitors are more effective and better tolerated than the second-line single agent chemotherapy [4–7], thus representing the new standard of care for NSCLC patients who experienced progression after platinum-combinations.